SCHEMBL6449880

SCHEMBL6449880

OC(CC1CNCCN1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.43
CYP2D6 P10635 3/20 0.43
CYP1A2 P05177 2/20 0.43
HIF1A Q16665 1/20 0.43
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RIPK1 Q13546 1/20 0.38
GBA1 P04062 1/20 0.36
AOC3 Q16853 3/20 0.36
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6451095 1.00 LTA4H (0.43) LTA4HCYP2D6CYP1A2HIF1ALMNA
SCHEMBL5563536 1.00 LTA4H (0.43) LTA4HCYP2D6CYP1A2HIF1ALMNA
SCHEMBL28217918 0.85 LTA4H (0.47) LTA4H
SCHEMBL14364976 0.81 LTA4H (0.42) LTA4HCYP2D6GBA1
SCHEMBL20832991 0.79 CYP2D6 (0.56) CYP2D6CYP1A2HIF1ALMNAKDM4E
SCHEMBL22259900 0.79 CYP2D6 (0.56) CYP2D6CYP1A2HIF1ALMNAKDM4E
SCHEMBL8507267 0.79 CYP2D6 (0.56) CYP2D6CYP1A2HIF1ALMNAKDM4E
SCHEMBL20833013 0.79 CYP2D6 (0.56) CYP2D6CYP1A2HIF1ALMNAKDM4E
SCHEMBL18284812 0.79 LTA4H (0.38) LTA4HGBA1
SCHEMBL10679403 0.77 CYP2D6 (0.62) CYP2D6CYP1A2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1492794-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS ELI LILLY AND COMPANY (US) 2005-01-05 EP disclosed
WO-2003082877-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS ELI LILLY AND COMPANY (US) 2003-10-09 WO disclosed